A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.
Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai BR, Van Daele M, Love D, Haga Y, Romaniello D, Salame TM, Zerbib M, Oren R, Tsutsumi Y, Lauriola M, Marrocco I, Yarden Y.
Simoni-Nieves A, et al. Among authors: haga y.
Cell Rep Med. 2024 Sep 17;5(9):101703. doi: 10.1016/j.xcrm.2024.101703. Epub 2024 Aug 30.
Cell Rep Med. 2024.
PMID: 39216477
Free article.